Baxter International Inc., through its subsidiaries, develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The company operates in two segments, BioScience and Medical Products. The BioScience segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; products for regenerative medicine, such as biosurgery products; and certain vaccines. The Medical Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics. It also provides products and services related to pharmacy compounding, drug formulation, and packaging technologies; and to treat end-stage renal disease or irreversible kidney failure. In addition, this segment manufactures solutions and other products for peritoneal dialysis, a home-based therapy; and distributes products for hemodialysis, which is conducted in a hospital or clinic. Baxter International Inc. serves hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctorsí offices, clinical and medical research laboratories, and patients at home under physician supervision primarily in the United States, Europe, the Asia-Pacific, Latin America, and Canada. The company sells its products through its direct sales force, as well as to and through independent distributors, drug wholesalers, and specialty pharmacy and homecare companies. It has a strategic partnership with MaRS Innovation to commercialize early-stage technologies Baxter International Inc. was founded in 1931 and is based in Deerfield, Illinois.